Imuldosa (Ustekinumab)

Ustekinumab is a fully human monoclonal antibody that binds the p40 subunit common to interleukin‑12 and interleukin‑23. By blocking these cytokines from interacting with their receptors, it suppresses the Th1 and Th17 inflammatory pathways, reducing the immune‑mediated inflammation that drives the listed diseases.

The dosing regimen for Imuldosa is individualized by the prescribing physician based on the specific indication, patient weight, and clinical response. The healthcare provider determines the initial intravenous loading dose and any subsequent maintenance infusions, following the product’s prescribing information and relevant clinical guidelines.

Safety data for ustekinumab in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies. Breastfeeding mothers should discuss potential exposure with their healthcare provider before continuing treatment.

To request Imuldosa, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if required—and necessary import documentation.

Compared with other biologics such as TNF‑α inhibitors or IL‑17 blockers, ustekinumab targets a different cytokine pathway (IL‑12/23). This distinct mechanism can be advantageous for patients who have inadequate response or intolerance to other classes. Clinical studies show comparable efficacy in skin clearance, with a dosing schedule that may be less frequent than some alternatives, though individual response varies.

Imuldosa should be stored refrigerated at 2 °C to 8 °C (36 °F to 46 °F). The product must be kept in its original packaging to protect it from light, and it should never be frozen or shaken. If temporary storage at controlled room temperature is unavoidable, it should not exceed the time limits specified in the product labeling.

Imuldosa is supplied as a sterile solution for intravenous infusion. The initial dose is given as a weight‑based loading infusion in a clinical setting, followed by maintenance infusions at intervals defined by the prescribing information. Administration must be performed by qualified healthcare personnel, with appropriate monitoring for infusion‑related reactions during and after the procedure.

The most serious risks include the development of serious infections such as tuberculosis or opportunistic pathogens, hypersensitivity reactions that can be life‑threatening, and a potential increased incidence of malignancies. Patients should be screened for latent infections before starting therapy, monitored regularly for signs of infection, and evaluated for any unexpected symptoms that could indicate severe adverse events.

Imuldosa is contraindicated in patients with known hypersensitivity to ustekinumab or any of the product’s excipients. It should also be avoided in individuals with active, uncontrolled infections, including untreated tuberculosis, and in those receiving live vaccines. Clinicians must assess each patient’s medical history and current conditions to determine suitability before initiating treatment.